emerge semaglutide Popular GLP-1 drug may slow down biological aging, analysis indicates Come on in and see

Further trials are needed to investigate whether GLP-1 agonists, and particularly with more effective weekly agents (i.e

The results of the Phase 3 SYNCHRONIZE-1 trial, recently published in the New England Journal of Medicine, highlight the potential of survodutide as a new therapeutic option for adults with obesity

prescription classification

Reach out to learn how were helping providers and patients with tailored metabolic solutions

Through its unique mechanism of action as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, as well as its impressive results in clinical trials, tirzepatide has the potential to completely transform the current approach to treating obesity

Discover the most popular peptides, including GP1s, HGH & more